Repository of University of Nova Gorica

Show document
A+ | A- | SLO | ENG

Title:Vpliv metformina in sorodnih ksenobiotikov na viabilnost celic raka dojke
Authors:Klemenčič, Sara (Author)
Petan, Toni (Mentor) More about this mentor... New window
Files:.pdf Sara_Klemencic.pdf (1,08 MB)
 
Language:Slovenian
Work type:Bachelor thesis/paper (mb11)
Tipology:2.11 - Undergraduate Thesis
Organization:FZO - Faculty of Environmental Sciences
Abstract:Farmacevtska industrija se danes med drugim sooča tudi z negativnimi vplivi svojih proizvodov na okolje. Tak primer je metformin, ki spada med najpogosteje predpisana zdravila v procesih zdravljenja diabetesa tipa II in je hkrati v fazi kliničnih raziskav kot zdravilo za zdravljenje rakavih obolenj. Deluje tako, da zavira celično dihanje, niža proizvodnjo ATP in aktivira z AMP-aktivirano protein kinazo (AMPK), ki je glavni metabolični senzor v evkariontskih celicah. V diplomskem delu smo želeli ugotoviti, ali metformin in sorodni ksenobiotiki, povezani z delovanjem AMPK (spojina C in bromokrotonska kislina), vplivajo na rast visoko invazivnih celic adenokarcinoma dojke MDA-MB-231. To smo storili s pomočjo spektrofluorimetričnega testa viabilnosti z barvilom Presto Blue, ki temelji na sposobnosti zdravih celic, da reducirajo barvilo po vstopu v celico. Pokazali smo, da obstaja linearna zveza med številom celic MDA-MB-231 v populaciji in fluorescenčnim signalom barvila, kar potrjuje ustreznost izbrane metode. Celice smo gojili 48 h pri optimalnih pogojih in v prisotnosti različnih koncentracij vsake od treh učinkovin. Pokazali smo, da viabilnost celic pojema z naraščanjem koncentracije učinkovine. Rezultati kažejo, da inhibicija kataboličnih in oksidativnih procesov v celici (mitohondrijsko dihanje, oksidacija maščobnih kislin in aktivacija AMPK) negativno vpliva na rast in preživetje celic MDA-MB-231. Z našimi rezultati smo prispevali k boljšemu razumevanju mehanizma delovanja metformina in sorodnih zdravilnih učinkovin usmerjenih proti kataboličnemu metabolizmu.
Keywords:viabilnost, metformin, bromokrotonska kislina, spojina C, dorzomorfin, AMPK, rak dojke, MDA-MB-231
Year of publishing:2017
Source:Nova Gorica
COBISS_ID:4650491 Link is opened in a new window
URN:URN:SI:UNG:REP:IH2OH7AY
Views:5839
Downloads:158
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Categories:Document is not linked to any category.
:
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Secondary language

Language:Undetermined
Title:The effect of metformin and associated xenobiotics on the viability of breast cancer cells
Abstract:The pharmaceutical industry is often confronted with the negative effects of their products on the environment. A good example is metformin, one of the most frequently prescribed drugs in the treatment of type II diabetes, which is currently also in clinical trials for the treatment of cancer. It inhibits cell respiration, reduces the production of ATP and activates AMP-activated protein kinase (AMPK), which is the main metabolic sensor in eukaryotic cells. The aim of this work was to determine whether metformin and related xenobiotics, associated with the activity of AMPK (compound C and bromocrotonic acid), affect the growth of the highly invasive MDA-MB-231 breast adenocarcinoma cells. The effects of these pharmacological agents on breast cancer cell growth were determined with a spectrofluorimetric viability assay using the Presto Blue dye, which is based on its ability to undergo reduction upon entering healthy cells. We found that there is a linear relationship between the number of MDA-MB-231 cells in the population and Presto Blue fluorescence intensity, which confirms the suitability of the chosen method. The cells were cultured for 48 h under optimal conditions in the presence of various concentrations of each of the three compounds. The results show that the viability of MDA-MB-231 cells decreases with increasing concentrations of each agent. This suggests that inhibition of catabolic and oxidative processes in MDA-MB-231 cells (mitochondrial respiration, fatty acid oxidation and activation of AMPK) adversely affects their growth and survival. Our results contribute to a better understanding of the mechanism of action of metformin and other pharmacological agents targeting catabolic metabolism.
Keywords:cell viability, metformin, bromocrotonic acid, compound C, dorsomorphin, AMPK, breast cancer, MDA-MB-231


Back